Abstract
Over three years following the discovery of the TAL code, artificial TAL effector DNA binding domains have emerged as the premier platform for building site-specific DNA binding polypeptides for use in biological research. Here, we provide an overview of TAL effector and alternative modular DNA binding domain (mDBD) technologies, focusing on their use in established and emerging architectures for building site-specific endonucleases for genome engineering applications. We also discuss considerations for choosing TAL effector/mDBD or alternative nuclease technologies for genome engineering projects ranging from basic laboratory gene editing of cultured cell lines to therapeutics. Finally, we highlight how the rapid pace of development of mDBD-based, such as monomeric TALENs (I-TevI-TAL), and more recently RNA-guided nucleases (CRISPR-Cas9) has led to a transition in the field of genome engineering towards development of the next generation of technologies aimed at controlling events that occur after targeted DNA breaks are made.
Keywords: DNA repair, double strand break, exonuclease, genome engineering, homing endonuclease, meganuclease, nuclease, TALEN, ZFN, zinc finger nuclease.
Current Gene Therapy
Title:Genome Engineering with TAL-Effector Nucleases and Alternative Modular Nuclease Technologies
Volume: 13 Issue: 4
Author(s): Andrew M. Scharenberg, Philippe Duchateau and Julianne Smith
Affiliation:
Keywords: DNA repair, double strand break, exonuclease, genome engineering, homing endonuclease, meganuclease, nuclease, TALEN, ZFN, zinc finger nuclease.
Abstract: Over three years following the discovery of the TAL code, artificial TAL effector DNA binding domains have emerged as the premier platform for building site-specific DNA binding polypeptides for use in biological research. Here, we provide an overview of TAL effector and alternative modular DNA binding domain (mDBD) technologies, focusing on their use in established and emerging architectures for building site-specific endonucleases for genome engineering applications. We also discuss considerations for choosing TAL effector/mDBD or alternative nuclease technologies for genome engineering projects ranging from basic laboratory gene editing of cultured cell lines to therapeutics. Finally, we highlight how the rapid pace of development of mDBD-based, such as monomeric TALENs (I-TevI-TAL), and more recently RNA-guided nucleases (CRISPR-Cas9) has led to a transition in the field of genome engineering towards development of the next generation of technologies aimed at controlling events that occur after targeted DNA breaks are made.
Export Options
About this article
Cite this article as:
Scharenberg M. Andrew, Duchateau Philippe and Smith Julianne, Genome Engineering with TAL-Effector Nucleases and Alternative Modular Nuclease Technologies, Current Gene Therapy 2013; 13 (4) . https://dx.doi.org/10.2174/15665232113139990026
DOI https://dx.doi.org/10.2174/15665232113139990026 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Science Ph.D. and Science Postdoctoral Advisors for the 21st Century: A Path To Successful Technology Transfer
Technology Transfer and Entrepreneurship (Discontinued) Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology TGF-β Signaling in Gastrointestinal Cancer Stem Cells
Current Cancer Therapy Reviews Stress, Depression and Hippocampal Apoptosis
CNS & Neurological Disorders - Drug Targets Down-Regulation of Angiogenic Inhibitors: A Potential Pathogenic Mechanism for Diabetic Complications
Current Diabetes Reviews Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology:Theory, Data Acquisition,Analysis, and Examples
Current Medical Imaging MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Vitamin D Insufficiency and Diabetes Risks
Current Drug Targets Imiquimod 5% Cream Use in Dermatology, Side Effects and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Application of PET to the Diagnosis, Staging, and Treatment of Locally Advanced Non-small Cell Lung Cancer
Current Medical Imaging Pharmacogenetics and the Pharmaceutical Industry
Current Pharmaceutical Design Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science Methotrexate: A Drug of the Future in Ulcerative Colitis?
Current Drug Targets Molecular Mechanisms of Epithelial Regeneration and Neovascularization During Healing of Gastric and Esophageal Ulcers
Current Medicinal Chemistry Alternative Medicine Safety: Agaricus blazei and Propolis
Combinatorial Chemistry & High Throughput Screening Endothelial Progenitor Cells in Prehypertension
Current Pharmaceutical Design Meet Our Associate Editor
MicroRNA